GRI
HEALTHCAREGRI Bio Inc
Live · NASDAQ · May 9, Close
What's Moving GRI Today?
No stock-specific AI insight has been generated for GRI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.36
Fundamentals
Trading
GRI News
20 articles- GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory ConditionsYahoo Finance·Apr 8, 2026
- How The Grainger (LSE:GRI) Investment Story Is Evolving As The Narrative Holds SteadyYahoo Finance·Apr 4, 2026
- 3 Undervalued Small Caps In Global With Recent Insider ActivityYahoo Finance·Apr 2, 2026
- GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” SegmentYahoo Finance·Feb 17, 2026
- JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026Yahoo Finance·Feb 9, 2026
- GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull FinancialYahoo Finance·Feb 5, 2026
- GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent HighlightsYahoo Finance·Feb 4, 2026
- GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPFYahoo Finance·Jan 28, 2026
- GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound StructuresYahoo Finance·Jan 26, 2026
- GRI Bio Announces Reverse Stock SplitYahoo Finance·Jan 21, 2026
- GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621Yahoo Finance·Jan 8, 2026
- GRI Bio Announces Closing of $8.0 Million Public OfferingYahoo Finance·Dec 12, 2025
- GRI Bio Announces Pricing of $8,000,000 Million Public OfferingYahoo Finance·Dec 11, 2025
- GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)Yahoo Finance·Dec 10, 2025
- Sector Update: Health Care Stocks Climb Late AfternoonYahoo Finance·Sep 11, 2025
- Sector Update: Health Care Stocks Higher Thursday AfternoonYahoo Finance·Sep 11, 2025
- GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)Yahoo Finance·Sep 11, 2025
- GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 3, 2025
- JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025Yahoo Finance·Aug 15, 2025
- GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechYahoo Finance·Aug 14, 2025
All 20 articles loaded
Price Data
52-Week Range
$2.36
Fundamentals
Trading
About GRI Bio Inc
GRI Bio Inc. is a cutting-edge biotechnology company focused on revolutionizing patient care through its proprietary microbiome technology platform. With a strong emphasis on developing innovative therapies specifically targeting unmet medical needs in immunology and oncology, GRI Bio strives to tackle the underlying causes of diseases rather than just their symptoms. The company has established a robust pipeline of product candidates and strategic research partnerships, positioning it for notable growth and a leadership role in the burgeoning field of microbiome therapeutics. Committed to enhancing patient outcomes, GRI Bio is well-equipped to make significant contributions to the future of healthcare solutions.